Brief: Cantargia Publishes Clinical Trial Results With Nadunolimab And Pembrolizumab
06/05/2025 06:40
May 6 (Reuters) - Cantargia AB CANTA.ST: PUBLISHES CLINICAL TRIAL RESULTS WITH NADUNOLIMAB AND PEMBROLIZUMAB TRIAL SHOWS ACCEPTABLE SAFETY PROFILE AND MEDIAN OVERALL SURVIVAL OF 19.7 MONTHS OBSERVED COMBINATION THERAPY SHOWS 60% DISEASE CONTROL RATE Source text: ID:nMFN1yG6FS Further company coverage: CANTA.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Cantargia AB
See all newsBrief: Cantargia Publishes Nadunolimab CANFOUR Study Data
Brief: Cantargia Announces Outcome Of Rights Issue, Raising About SEK 75 Mln
Brief: Cantargia Carries Out Rights Issue, Enters Loan Agreement
Brief: Cantargia Q1 Operating Loss Narrows To SEK 36.9 Mln
Brief: Cantargia: Early Results From Phase 1B/2A Nadunolimab Trial In MDS And AML